Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum
06 Agosto 2009 - 7:25AM
PR Newswire (US)
Company Presents Data on Menstrual Stem Cells at Global Stem Cell
Research Symposium OLDSMAR, Fla., Aug. 6 /PRNewswire-FirstCall/ --
Cryo-Cell International, Inc. (OTC:CCEL) (BULLETIN BOARD: CCEL) ,
one of the largest and most established leaders in stem cell
innovation, will present data on the proliferative ability of stem
cells found in menstrual blood (known as MenSCs) during the Fourth
China Medical Biotech Forum, August 8-10 in Dalian, China. Data
from an in vitro study show that MenSCs proliferate rapidly and
have significant potential to develop into multiple cell types. Dr.
Julie Allickson, Vice President of Laboratory Operations and
Research and Development at Cryo-Cell, will present the data at the
Forum as part of a keynote address. Study Overview The data being
presented are based on research conducted by Cryo-Cell
International, who discovered the menstrual stem cells. The data
show that MenSCs have the capability to differentiate rapidly and
plentifully into stem cells, such as bone, cartilage, fat, nerve
and cardiogenic cells. These findings demonstrate that menstrual
stem cells are easily expandable to clinical relevance and may
potentially have applications in a variety of conditions. Using
Cryo-Cell's proprietary C'elle(SM) system, MenSCs are currently
being studied for potential therapeutic applications for possible
future treatment of disorders such as stroke; diabetes; vascular
regeneration; breast cancer; wound management; endometriosis and
female urinary incontinence. "We are pleased to share these
promising early study findings with the distinguished researchers
attending the CMBF," said Dr. Allickson. "MenSCs are sufficiently
potent and could potentially be used in the future for a variety of
therapies and conditions, and we look forward to gaining further
insights from the current clinical trials testing the safety and
efficacy of the cells in several different animal models." The
C'elle service is based on Cryo-Cell's expansive IP technology
portfolio and was introduced in November 2007 as the first and only
service that empowers women to collect and cryopreserve menstrual
flow containing undifferentiated adult stem cells for future
utilization by the donor or possibly first-degree relatives in a
manner similar to umbilical cord blood stem cells. Based on the
continuing success of MenSCs in the research setting, Cryo-Cell is
actively expanding its portfolio of research collaborations with
world renowned scientists committed to study this novel stem cell
population for a broad range of regenerative therapeutic
development. "Cryo-Cell's keynote presentation at the China Medical
Biotech Forum is a strategic opportunity that comes at an exciting
time for global stem cell research and development," stated
Mercedes A. Walton, Cryo-Cell's Chairman & CEO. "The Company
continues to build a robust intellectual property portfolio based
on Cryo-Cell's menstrual stem cell technology. We are honored to
share the Company's research with preeminent scientists and
physicians who are attending the China Medical Biotech Forum from
around the world." About the China Medical Biotech Forum The Forum
invites officers from related government departments of China to
give special reports on key issues and relevant policies regarding
the development of medicinal biotechnology. It also provides
renowned scientists the opportunity to make presentations on their
latest progress. Presentations focus on topics such as vaccine
separation, purification and application; antibody and peptide drug
research and clinical application; the latest developments of
enzyme engineering and fermentation engineering; as well as
regenerative medicine technology research and its standard,
nanobiotechnology research. About C'elle The C'elle(SM) service was
introduced in November 2007 as the first and only service that
empowers women to collect and cryopreserve menstrual flow
containing undifferentiated adult stem cells for future utilization
by the donor or possibly their first-degree relatives in a manner
similar to umbilical cord blood stem cells. For more information,
visit http://www.celle.com/. About Cryo-Cell International, Inc.
(OTCBB: CCEL.OB) Based in Oldsmar, Florida, with nearly 185,000
clients worldwide, Cryo-Cell is one of the largest and most
established family cord blood banks. ISO 9001:2000 certified and
accredited by the AABB, Cryo-Cell operates in a state-of-the-art
Good Manufacturing Practice and Good Tissue Practice
(cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded
company. OTC Bulletin Board Symbol: CCEL. For more information,
please call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.cryo-cell.com/. Forward-Looking Statement Statements
wherein the terms "believes", "intends", "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the
Company. The information contained herein is subject to various
risks, uncertainties and other factors that could cause actual
results to differ materially from the results anticipated in such
forward-looking statements or paragraphs, many of which are outside
the control of the Company. These uncertainties and other factors
include the uncertainty of market acceptance of any potential
service offerings relating to types of stem cells other than cord
blood stem cells, including the C'elle service, given that
menstrual stem cells and other new stem cells have not yet been
used in human therapies, and treatment applications using such stem
cells may not be developed and commercialized; or if they are not
likely to be developed or commercialized for many years and are
subject to further research and development; the need for
additional development and testing before determining the ultimate
commercial value of the Company's intellectual property relating to
the menstrual stem cells; the need to complete certain
developments, including completion of clinical validation and
testing, before any new process other than C'elle can be
commercialized, and the Company's development of its final business
and economic model in offering any such service; any adverse effect
or limitations caused by recent increases in government regulation
of stem cell storage facilities; any increased competition in our
business; any decrease or slowdown in the number of people seeking
to store stem cells or decrease in the number of people paying
annual storage fees; any technological breakthrough or medical
breakthrough that would render the Company's business of stem cell
preservation obsolete; and any other risk factors described in our
filing with the Securities and Exchange Commission. The foregoing
list is not exhaustive, and the Company disclaims any obligations
to subsequently revise any forward-looking statements to reflect
events or circumstances after the date of such statements. Readers
should also carefully review the risk factors described in other
documents the Company files from time to time with the Securities
and Exchange Commission, including the most recent Annual Report on
Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current
Reports on Form 8-K filed by the Company. Contact: General Media
Inquiries Kristin Boza 312-233-1295 Financial Media Inquiries:
Cryo-Cell International, Inc. Investor Relations Dianne Will
518-398-6222 DATASOURCE: Cryo-Cell International, Inc. CONTACT:
General Media, Kristin Boza, +1-312-233-1295, ; or Financial Media,
Dianne Will, Investor Relations, Cryo-Cell International, Inc.,
+1-518-398-6222, Web Site: http://www.cryo-cell.com/
Copyright